WATERTOWN, Mass.--(BUSINESS WIRE)--Dec. 21, 2005--Acusphere, Inc. (NASDAQ:ACUS) today announced that it has cumulatively enrolled 700 patients in the pivotal Phase 3 clinical program for AI-700, its lead product candidate. AI-700 is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing, currently the leading procedure for detecting coronary heart disease. The Company also announced that it has instructed clinical sites in one of its two concurrent pivotal trials in this program, the “32" trial, to suspend further patient enrollment because the Company believes that it has enrolled a sufficient number of patients in that trial for the results to be able to achieve statistical significance.
